QIAGEN N.V. (QGEN) 2025 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Ladies and gentlemen, thank you for standing by. I am Katie, your call operator. Welcome, and thank you for joining Qiagen's fourth quarter 2025 earnings conference call webcast. (Operator Instructions). At this time, I'd like to introduce your host, Daniel Wendorff, Vice President of Head of Relations at Qiagen's. Please go ahead.

    女士們、先生們,感謝你們的耐心等待。我是凱蒂,您的接線生。歡迎參加 Qiagen 2025 年第四季財報電話會議網路直播,感謝您的參與。(操作說明)此時,我謹向大家介紹主持人丹尼爾‧溫多夫,他是凱傑公司關係副總裁兼負責人。請繼續。

  • Daniel Wendorff - Vice President of Head of Relations

    Daniel Wendorff - Vice President of Head of Relations

  • Thank you, operator, and welcome to our call for the fourth quarter of 2025. We appreciate your time and interest in Qiagen. Joining on the call today are Thierry Bernard, our Chief Executive Officer; and Roland Sackers, our Chief Financial Officer. Also joining us is Dr. Domenica Martorana from our Investor Relations team.

    謝謝接線員,歡迎參加我們2025年第四季的電話會議。感謝您抽空關注Qiagen。今天參加電話會議的有我們的執行長 Thierry Bernard 和我們的財務長 Roland Sackers。同時出席的還有來自投資者關係團隊的 Domenica Martorana 博士。

  • As always, today's call is being webcast live and will be archived in the IR section of our website at www.Qiagen.com, where you can find the press release and presentation accompanying this call. Please also note that this call will include forward-looking statements.

    與往常一樣,今天的電話會議將進行網路直播,並將在我們的網站 www.Qiagen.com 的投資者關係部分進行存檔,您可以在那裡找到與本次電話會議相關的新聞稿和簡報。另請注意,本次電話會議將包含前瞻性陳述。

  • Actual results may differ materially from those projected due to a number of factors outlined in our most recent Form 20F and other filings with the US Securities and Exchange Commission. We will also refer to certain financial measures not prepared in accordance with US.

    由於我們在最新的 20F 表格和向美國證券交易委員會提交的其他文件中列出的許多因素,實際結果可能與預測結果有重大差異。我們也會提及一些不符合美國財務準則的財務指標。

  • Generally Accepted Accounting Principles or GAAP that provide additional insights into our performance. Reconciliations to the most directly comparable GAAP figures are in the release and presentation. All references to earnings per share refer to adjusted diluted EPS. With that, let me hand the call over to Thierry.

    一般公認會計原則(GAAP)為我們提供了更多有關業績的見解。與最直接可比較的 GAAP 數據的調整表已在新聞稿和簡報中列出。所有提及的每股收益均指調整後稀釋每股收益。那麼,就讓我把電話交給蒂埃里吧。

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • Thanks a lot, Daniel. Hello, and good morning, good afternoon or good evening, depending on where you are in the world, and thank you once again for joining us. I am very pleased today to confirm that Qiagen continued to perform and delivered a solid finish to 25 with results in the fourth quarter again above outlook.

    非常感謝,丹尼爾。您好,早上好、下午好或晚上好,這取決於您身處世界的哪個地方,再次感謝您的參與。我今天非常高興地確認,凱傑公司繼續保持良好業績,並在25日取得了穩健的收官,第四季度業績再次超出預期。

  • We exceeded our targets for both sales and adjusted earnings, once again placing Qiagen among the fastest-growing companies in our industry. This reflects continued execution across the business and the trust our customers place in us even in a challenging environment.

    我們在銷售額和調整後收益方面均超額完成了目標,再次使 Qiagen 躋身業內成長最快的公司之列。這反映了公司在各個業務領域持續高效的執行力,以及即使在充滿挑戰的環境下,客戶對我們的信任。

  • I also want to recognize the dedication of our teams around the world. Their work has been essential in delivering those results. So let me walk you through our key messages for today.

    我還要感謝我們世界各地團隊的奉獻精神。他們的工作對取得這些成果至關重要。那麼,讓我來為大家梳理一下我們今天的主要訊息。

  • First, we exceeded our outlook for the fourth quarter, and we also delivered solid full year 2025 results at the high end of our expectation with adjusted earnings again above our guidance. Net sales were $540 million in the fourth quarter.

    首先,我們超越了第四季度的預期,並且2025年全年業績也達到了預期的高端水平,調整後的收益再次超過了我們的指導。第四季淨銷售額為5.4億美元。

  • growing 1% at CER and exceeding our outlook for flat sales development against the fourth quarter of '24. Adjusted diluted EPS was $0.62 at constant exchange rate, exceeding our outlook of about $0.60 constant exchange rate again.

    以固定匯率計算成長 1%,超過了我們對 2024 年第四季銷售額持平的預期。以固定匯率計算,調整後的稀釋每股收益為 0.62 美元,再次超過了我們先前預測的約 0.60 美元(以固定匯率計算)。

  • For the full year of 2025, net sales were $2.09 billion, up 5% at CER and at the upper end of our outlook of about 4% to 5% growth. Adjusted diluted EPS increased to $2.40 at CER. This was above our outlook, which we increased twice during the year and reflects our ability to deliver in a challenging environment.

    2025 年全年淨銷售額為 20.9 億美元,以固定匯率計算成長 5%,達到我們先前預測的 4% 至 5% 成長的上限。以固定匯率計算,調整後稀釋每股盈餘增加至 2.40 美元。這高於我們的預期,我們在年內兩次上調了預期,這反映了我們在充滿挑戰的環境中實現目標的能力。

  • Second key message, we reached important milestones across our portfolio. We want to highlight here that across our growth pillars, sample technologies, QuantiFERON, QIAstat, QIAcuity and Qiagen Digital Insights.

    第二個重要訊息是,我們的投資組合中各項業務都取得了重要的里程碑式進展。我們想在此強調,在我們的成長支柱中,樣本技術包括 QuantiFERON、QIAstat、QIAcuity 和 Qiagen Digital Insights。

  • They all achieved combined sales of $1.49 billion at CER in '25, delivering 8% growth at CER again. The current trajectory keeps us on track for at least $2 billion in combined sales from our growth pillars by 2028. This reflects continued demand across our portfolio and the increasing relevance from areas where we have decided to invest for the long-term growth.

    2025 年,它們的總銷售額按固定匯率計算為 14.9 億美元,再次實現了 8% 的成長。按照目前的發展軌跡,到 2028 年,我們各成長支柱的總銷售額將至少達到 20 億美元。這反映了我們投資組合的持續需求,以及我們決定投資以實現長期成長的領域的重要性日益增加。

  • Sample Technologies continued to grow with sales up at CER in the fourth quarter and 2% CER gain for the full year. This is an indication of the demand for automated consumables as laboratories continue to push to automated sample prep.

    Sample Technologies 第四季銷售額以固定匯率計算持續成長,全年以固定匯率計算成長 2%。這表明,隨著實驗室不斷推進自動化樣品製備,對自動化耗材的需求也不斷增長。

  • In addition, during the year, we completed the acquisition of Par Biosciences extending sample technologies into single cell analysis and adding exposure to this very rapidly scaling field. QuantiFERON delivered continued growth with sales up 5% at CER in the fourth quarter and 10% CER again for the full year, supported by ongoing conversion and a large and still underpenetrated latent TB testing market. We are executing here on a clear strategy to drive further conversion.

    此外,在這一年中,我們完成了對 Par Biosciences 的收購,將樣本技術擴展到單細胞分析領域,並增加了在這個快速發展的領域的曝光。QuantiFERON 第四季銷售額以固定匯率計算成長 5%,全年以固定匯率計算成長 10%,這得益於持續的轉換率提升以及龐大但滲透率仍然較低的潛伏性結核病檢測市場。我們正在執行一項明確的策略,以進一步提高轉換率。

  • QIAcuity our digital PCR solution delivered double-digit growth in consumables and an installed base that exceeded 3,200 instruments globally since we launched it. as digital PCR continues to gain relevance in applications requiring high precision and QIAstat grew 15% at CER in the fourth quarter and 24% CER for the full year 2025.

    自推出以來,我們的數位PCR解決方案QIAcuity的耗材銷量實現了兩位數成長,全球裝置已超過3,200台。隨著數位PCR在需要高精度的應用中日益普及,QIAstat在第四季度以固定匯率計算增長了15%,預計2025年全年按固定匯率計算增長24%。

  • Growth was supported by menu expansion and the growing installed base that exceeded 5,200 instruments. Last, our bioinformatic business, Qiagen Digital Insights, delivered continued growth in 2025, supported by demand across both Discovery research and academia and clinical customers and the integration of Genoox, which further strengthened our clinical interpretation offering.

    菜單擴展和不斷增長的安裝基數(超過 5200 台儀器)支撐了增長。最後,我們的生物資訊學業務 Qiagen Digital Insights 在 2025 年實現了持續成長,這得益於探索性研究、學術界和臨床客戶的需求,以及 Genoox 的整合,這進一步加強了我們的臨床解讀服務。

  • Third message for today. We made further progress on profitability and cash flow while continuing to execute on disciplined capital allocation.

    今天的第三條消息。我們在獲利能力和現金流方面取得了進一步進展,同時繼續執行嚴格的資本配置。

  • For 2025, our adjusted operating income margin increased 80 basis points to 29.5%, reflecting continued efficiency gains across the business. Those improvements more than offset headwinds from tariffs or adverse currency movements and the previously disclosed dilutive impact from recent acquisitions. We also generated solid free cash flow of $453 million in 2025.

    2025 年,我們調整後的營業利潤率提高了 80 個基點,達到 29.5%,反映出公司業務效率的持續提高。這些改善足以抵銷關稅或不利匯率波動帶來的不利影響,以及先前揭露的近期收購帶來的稀釋影響。我們也預計在 2025 年將產生 4.53 億美元的穩健自由現金流。

  • This supported investment into the business, including the rollout of our upgraded ERP programs. At the same time, we continue to return capital to shareholders. Since 2024, Qiagen has returned more than $1.1 billion to shareholders to date and introduced an annual dividend payment while pursuing selective bolt-on acquisitions to support our future growth.

    這為公司提供了投資,包括推出升級的 ERP 程式。同時,我們繼續向股東返還資本。自 2024 年以來,Qiagen 已向股東返還超過 11 億美元,並引入了年度股息支付制度,同時進行選擇性的補充收購以支持我們未來的成長。

  • So as we are heading into 2026, we clearly remain focused on execution, disciplined cost management and continued investment into our growth pillars. Before handing over to Roland, I would also like to briefly acknowledge the change in our Supervisory Board.

    因此,在邁向 2026 年之際,我們將繼續專注於執行、嚴格的成本管理以及對我們成長支柱的持續投資。在將發言權交給羅蘭之前,我還想簡要地介紹一下我們監事會的變動。

  • We are very pleased to welcome Mark Stevenson, who joined our Supervisory Board in January. Mark brings deep operational and global life sciences experience and we really look forward to working with him. At the same time.

    我們非常高興地歡迎馬克史蒂文森先生於一月份加入我們的監事會。Mark擁有豐富的營運和全球生命科學經驗,我們非常期待與他合作。同時。

  • I would like to sincerely thank for his many years of contribution to Qiagen step down from the Supervisory Board after taking on a new leadership role at Memorial Sloan Kettering in New York, but we are grateful that he will continue to serve Qiagen as Chair of our Scientific Advisory Board. With that, I'll hand it over to Roland for more details on the financials.

    我衷心感謝他多年來對 Qiagen 的貢獻。他卸任監事會職務後,將在紐約紀念斯隆-凱特琳癌症中心擔任新的領導職務,但我們很欣慰他將繼續擔任 Qiagen 科學顧問委員會主席。接下來,我會把麥克風交給羅蘭,讓他詳細介紹一下財務狀況。

  • Roland Sackers - Managing Director, Chief Financial Officer, Member of the Executive Board

    Roland Sackers - Managing Director, Chief Financial Officer, Member of the Executive Board

  • Thank you, Thierry. Hello, everyone. Thank you as well for me for joining our call. We are pleased with our performance in the fourth quarter and full year as we delivered results above our outlook for the fourth quarter on both sales and adjusted diluted EPS at constant exchange rates. 2025 was overall another solid year for Qiagen in terms of execution and delivering on our commitments.

    謝謝你,蒂埃里。大家好。也感謝你參加我們的通話。我們對第四季度和全年的業績感到滿意,銷售額和按固定匯率計算的調整後攤薄每股收益均超出了第四季度的預期。 2025年對凱傑來說,在執行和履行承諾方面又是一個穩健的年份。

  • Let me frame our performance around three key messages.

    讓我圍繞著三個關鍵訊息來闡述我們的表演。

  • First, we delivered solid results with sales for '25 at the high end of our outlook with continued strength in consumables and our growth pillars amid a cautious funding and capital spending environment.

    首先,在謹慎的融資和資本支出環境下,我們取得了穩健的業績,2025 年的銷售額達到了我們預期的高端水平,消費品和我們的成長支柱業務持續強勁。

  • Second, we improved profitability expanding the adjusted operating income margin by 80 basis points over 24% on efficiency gains and operational discipline. These actions more than offset material headwinds from tariffs and currency movements. And third, we continue to deploy capital in a disciplined manner.

    其次,我們提高了獲利能力,透過提高效率和加強營運紀律,將調整後的營業利潤率提高了 80 個基點,超過 24%。這些措施足以抵銷關稅和匯率波動帶來的實質不利影響。第三,我們將繼續以嚴謹的方式部署資本。

  • We are investing to support future growth while increasing returns to shareholders. Our strong free cash flow enabled us to make investments into bolt-on yields like Parse and Genoox while also returning over USD1.1 billion to shareholders since 2024.

    我們進行投資是為了支持未來的成長,同時提高股東回報。我們強勁的自由現金流使我們能夠投資於 Parse 和 Genoox 等附加收益項目,同時自 2024 年以來向股東返還了超過 11 億美元。

  • With that context, let me focus on the financial drivers behind our results. For the fourth quarter, net sales grew 1% CER and exceeded our outlook for flat sales development against '24.

    基於上述背景,讓我重點談談我們業績背後的財務驅動因素。第四季淨銷售額以固定匯率計算成長 1%,超過了我們先前對 2024 年銷售額持平的預期。

  • Adjusted diluted EPS was $0.62 at CER and above our outlook for about $0.60. For the full year, sales increased 5% CER, and this was at the high end of our outlook. Our growth pillars delivered 8% CER growth for the year and reached our goal for $1.49 billion of combined sales at CER.

    經調整後的稀釋每股收益以固定匯率計算為 0.62 美元,高於我們先前約 0.60 美元的預期。全年銷售額以固定匯率計算成長 5%,達到我們預期的上限。我們的成長支柱實現了 8% 的固定匯率成長,並達到了 14.9 億美元的固定匯率合併銷售額目標。

  • So we are on track to achieve our '28 goal for at least $2 billion of combined sales from these products. Adjusted diluted EPS for the full year were $2.40 at CER for '25, which was $0.12 above our initial outlook for the year and compares with $2.18 in '24.

    因此,我們預計將實現 2028 年這些產品總銷售額至少達到 20 億美元的目標。2025 年全年調整後稀釋每股收益為 2.40 美元(以固定匯率計算),比我們最初的預期高出 0.12 美元,而 2024 年為 2.18 美元。

  • Let me now provide some additional insights into sales trends for the fourth quarter and for '25. Among our product groups, Sample technologies delivered mid-single-digit CER growth for the fourth quarter and this was complemented by low single-digit growth in Diagnostic Solutions and Genomics, while sales in our PCR product group declined at a single-digit rate.

    現在讓我再提供一些關於第四季和 2025 年銷售趨勢的見解。在我們的產品組中,樣本技術在第四季度實現了中等個位數的固定收益增長率,診斷解決方案和基因組學也實現了低個位數的增長,而我們的 PCR 產品組的銷售額則以個位數的速度下降。

  • In Sample technologies, sales growth in the fourth quarter was driven by higher demand for automated consumables used on our instruments, and results are included first-time contributions from the past acquisitions that was completed in December.

    在樣品技術領域,第四季度的銷售成長得益於對我們儀器使用的自動化耗材的更高需求,業績包含了 12 月完成的過去收購帶來的首次貢獻。

  • For the full year, Sample technologies delivered 2% CER growth in line with our expectations as trends improved over the course of the year. In Diagnostic Solutions, sales increased 1% in the fourth quarter.

    全年來看,Sample technologies 的 CER 成長率為 2%,符合我們的預期,因為全年趨勢有所改善。診斷解決方案業務第四季銷售額成長了 1%。

  • QIAstat-DX sales were up 15% CER, driven by double-digit growth in consumables as we continue to benefit on the full core menu in the US, '25 delivered 5% CER growth and supported by continued conversion from the skin test. In the PCI product group, sales declined 9% CER in the fourth quarter.

    QIAstat-DX 銷售額按固定匯率計算增長了 15%,這主要得益於耗材的兩位數增長,因為我們繼續受益於美國完整的核心菜單;2025 年,QIAstat-DX 銷售額按固定匯率計算增長了 5%,這得益於皮膚測試的持續轉化。PCI產品組第四季銷售額以固定匯率計算下降了9%。

  • Consumables for use on the QIAcuity Digital PCR system continued to deliver double-digit growth as we continue to place over 100 instruments per quarter in a challenging capital spending environment. Sales of other PCR consumables, however, declined due to factors that included the challenging funding environment and lower OEM contributions compared to the '24 period.

    在充滿挑戰的資本支出環境下,我們每季繼續投放超過 100 台儀器,QIAcuity 數位 PCR 系統的耗材持續保持兩位數的成長。然而,由於資金環境充滿挑戰以及與 2024 年相比 OEM 投入減少等因素,其他 PCR 耗材的銷售額有所下降。

  • In the genomics and NGS Product Group sales grew 2% CER in the fourth quarter, driven by double-digit growth in the Qiagen Digital Insights Bioinformatics business.

    第四季度,基因組學和 NGS 產品集團的銷售額按固定匯率計算增長了 2%,這主要得益於 Qiagen Digital Insights 生物資訊學業務的兩位數增長。

  • At the same time, sales of NGS consumables were under pressure. Turning to the regions in the Europe, Middle East, Africa region led the performance and were up 5% CER for the fourth quarter. top-performing countries included Belgium, the Netherlands, Spain and the United Kingdom. In the Americas, sales declined 1% CER with results in the United States being flat at constant exchange rates.

    同時,NGS耗材的銷售也面臨壓力。從歐洲、中東和非洲地區來看,這些地區表現最佳,第四季以固定匯率計算成長了5%。表現最佳的國家包括比利時、荷蘭、西班牙和英國。在美洲,銷售額以固定匯率計算下降了 1%,其中美國市場的業績以固定匯率計算持平。

  • A factor reflecting this was the US government shutdown. In the Asia Pacific, Japan region, sales were flat in the fourth quarter. Results in China declined at a low teen CER rate for the fourth quarter over the year-ago period. But keep in mind that this country represents only about 4% of total sales in '25.

    美國政府停擺就是反映這一點的一個因素。在亞太地區,尤其是日本地區,第四季銷售額持平。中國第四季業績年減幅度僅十幾個百分點。但請記住,這個國家在 2025 年的銷售額僅佔總銷售額的 4% 左右。

  • Turning to the full year results. For '25, the adjusted operating income margin was 80 basis points to 29.5% compared to '24. And this was achieved despite facing about 120 basis points of combined headwinds from tariffs and adverse currency movements.

    接下來看一下全年業績。2025 年調整後的營業利潤率比 2024 年下降了 80 個基點,達到 29.5%。儘管面臨關稅和不利匯率波動帶來的約 120 個基點的綜合不利因素,但仍取得了這項成果。

  • In other words, the underlying profitability strengthened meaningful during '25 -- excluding these external headwinds, the margin expanded by roughly 200 basis points in '25, and this was well above our initial target for at least 150 basis points of improvement and this was before the tariffs were announced.

    換句話說,2025 年基本獲利能力顯著增強——排除這些外部不利因素,2025 年利潤率擴大了約 200 個基點,這遠遠高於我們最初設定的至少 150 個基點的改善目標,而且這還是在關稅宣布之前。

  • This performance reinforces our confidence in exceeding our '28 target for a margin of at least 31%, and we are reviewing this target with plans to provide an update.

    這項業績增強了我們對實現 2028 年利潤率目標(至少 31%)的信心,我們正在重新評估這一目標,並計劃提供最新進展。

  • For the full year, we raised our adjusted EPS outlook price during '25 and ultimately delivered results of $2.38 on a reported basis and results at CER of $2.40. Turning to cash flow. Operating cash flow of '25 was $654 million compared with $674 million in '24, reflecting strong earnings generation.

    2025 年全年,我們提高了調整後每股收益預期,最終按報告數據計算的每股收益為 2.38 美元,按固定匯率計算的每股收益為 2.40 美元。接下來談談現金流。2025 年的營運現金流為 6.54 億美元,而 2024 年為 6.74 億美元,反映出強勁的獲利能力。

  • The results for '25 also absorbed about $54 million of cash payments for the efficiency initiatives. Free cash flow was $453 million for '25, reflecting higher capital expenditures related primarily to IT investments that included the SAP system upgrade.

    2025 年的業績還吸收了約 5,400 萬美元的現金支付,用於提高效率的措施。2025 年自由現金流為 4.53 億美元,反映資本支出增加,主要與 IT 投資有關,其中包括 SAP 系統升級。

  • We continue to deploy capital in a disciplined manner, balancing investment in the business with returns to shareholders. As you know, we completed the purchase of Parse in December while in January, we returned USD 500 million to shareholders through a synthetic share repurchase.

    我們將繼續以嚴謹的方式部署資本,在業務投資和股東回報之間取得平衡。如您所知,我們在 12 月份完成了對 Parse 的收購,而在 1 月份,我們透過合成股票回購向股東返還了 5 億美元。

  • On a pro forma basis, net leverage stood at about 1.3times net debt to adjusted EBITDA in January '26 as our leverage improves. Net financial flexibility to support continued investment in organic growth and targeted both on acquisitions while also increasing returns to shareholders and that also includes our annual dividend payments planned again from mid-'26.

    以備考基準計算,2026 年 1 月淨槓桿率約為淨債務與調整後 EBITDA 的 1.3 倍,因為我們的槓桿率有所改善。淨財務靈活性旨在支持對有機成長的持續投資,並專注於收購,同時增加股東回報,其中還包括我們計劃從 2026 年年中開始再次支付的年度股息。

  • Taken together, our '25 performance reflects solid execution on sales growth margin expansion and disciplined capital deployment as we look for another year of solid profitable growth in 2026.

    綜上所述,我們 2025 年的業績反映了銷售成長利潤率擴張和資本部署的穩健執行,我們期待 2026 年再創佳績,實現穩健獲利成長。

  • With that, let me hand the call back to Thierry.

    那麼,我把電話交還給蒂埃里。

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • Thanks a lot, Roland. And let me share with you a bit of perspective on our product portfolio. Starting with Sample technologies, as you know, a key focus for Qiagen. In December, we completed the acquisition of Parse Biosciences, extended our sample technologies portfolio into single sales analysis. Parse as a scalable differentiated chemistry that strengthens our Sample to Insight workflows and opens a long-term growth opportunity.

    非常感謝,羅蘭。接下來,我想和大家分享一下我對我們產品組合的一些看法。如您所知,樣品技術是 Qiagen 的重點關注領域。12 月,我們完成了對 Parse Biosciences 的收購,並將我們的樣品技術組合擴展到單一銷售分析領域。解析是一種可擴展的差異化化學方法,它增強了我們從樣品到洞察的工作流程,並開啟了長期成長的機會。

  • Recent launches such as ever code wall blood fixation enable immediate fixation at collection and extend Parse's reach into translational and clinical research. Alongside this expansion of acquisition, we execute on our next-generation automation road map. In 2025, we successfully launched QIAsymphony connect took initial orders for QIAsprint Connect and remain on track for the launch of QIAmini.

    最近推出的諸如 Evercode 壁血固定技術,可在採集時立即進行固定,並將 Parse 的應用範圍擴展到轉化和臨床研究領域。隨著收購範圍的擴大,我們正在執行下一代自動化路線圖。2025年,我們成功推出了QIAsymphony Connect,並獲得了QIAsprint Connect的首批訂單,目前正按計畫推進QIAmini的發布。

  • Within Sample technologies, strategic high-value applications to continue to gain traction. One example is our liquid bios sample preparation portfolio, which grew by more than 30%, reflecting this increasing relevance in Sample Technologies.

    在 Sample 技術領域,具有策略意義的高價值應用將持續獲得市場認可。例如,我們的液體生物樣品製備產品組合成長了 30% 以上,這反映了該產品在樣品技術領域日益增長的重要性。

  • Despite cautious capital spending, our sample technologies installed base grew to around 31,400 cumulative placements.

    儘管資本支出謹慎,但我們的樣本技術安裝基礎已成長到累計約 31400 套。

  • Looking 2026. We will launch QIAsprint Connect and QIAmini together with additional kits, supporting automation across more than 30 applications for QIAsprint Connect and more than 15 applications for QIAmini. Over time, this will increase instrument and recurring consumables. Full IVDR launch for QIAsymphony Connect remains on track for mid-2026.

    展望2026年。我們將同時推出 QIAsprint Connect 和 QIAmini,並提供額外的套件,支援 QIAsprint Connect 在 30 多個應用程式上的自動化,以及 QIAmini 在 15 多個應用程式上的自動化。隨著時間的推移,這將增加儀器和常用耗材的需求。QIAsymphony Connect 的 IVDR 全面發布仍按計劃進行,預計將於 2026 年年中發布。

  • QIAsprint Connect is planned for February and QIAmini for fall of 2026. Moving to QuantiFERON, where we continue to invest enabling laboratories to manage rising testing volumes with higher throughput and more efficient workflows.

    QIAsprint Connect 預定於 2026 年 2 月推出,QIAmini 計劃於 2026 年秋季推出。遷移到 QuantiFERON,我們將繼續投資,使實驗室能夠以更高的吞吐量和更有效率的工作流程來應對不斷增長的檢測量。

  • A key step here is the next generation of QuantiFERON TB Gold Plus second assay developed in collaboration with last year, we completed the European launch of this high throughput assay. This new generation of chemistry enables laboratories to test up to 75% more patients per hour while reducing turnaround time by around 25%.

    關鍵的一步是下一代 QuantiFERON TB Gold Plus 第二代檢測方法的開發,該方法是去年與合作夥伴共同開發的,我們已完成了這款高通量檢測方法在歐洲的推出。新一代化學技術使實驗室每小時能夠檢測的患者數量增加 75%,同時週轉時間縮短約 25%。

  • Building on this European launch, we are planning a US launch of this higher throughput chemistry in 2026. In parallel, we are also exploring how AI-based approaches can support clinical decision-making in latent TB infection, particularly in the context of increasing testing volumes and the need to guide preventive treatment.

    以歐洲的成功推出為基礎,我們計劃在 2026 年在美國推出這種高通量化學方法。同時,我們也在探索以人工智慧為基礎的方法如何支援潛伏性結核感染的臨床決策,尤其是在檢測量不斷增加和需要指導預防性治療的情況下。

  • Turning to QIAstat, where we expanded the menu and the installed base over the year. In '25, we submitted our first blood culture identification panels for clearance in the US.

    轉向 QIAstat,我們在過去一年中擴展了菜單和安裝基礎。2025年,我們向美國提交了第一批血液培養鑑定板以供批准。

  • and in Europe. These submissions extend QIAstat diagnostic into bloodstream infections and sepsis-related applications, building on panels across respiratory, gastrointestinal and meningitis testing. We also expanded the installed base with cumulative QIAstat placement exceeded 5,200 instruments worldwide in 2025.

    在歐洲也是如此。這些提交將 QIAstat 診斷擴展到血液感染和敗血症相關應用,並建立在呼吸道、胃腸道和腦膜炎檢測的基礎上。到了 2025 年,QIAstat 的累積安裝量在全球範圍內超過 5,200 台,進一步擴大安裝基礎。

  • We continue to invest in new panels particularly a panel for complicated urinary tract infections where Qiagen will be the first with a comprehensive syndromic solution. At the same time, we are also advancing our work on pneumonia panel.

    我們將繼續投資研發新的檢測板,特別是針對複雜尿路感染的檢測板,Qiagen 將成為首家提供全面綜合症解決方案的公司。同時,我們也在推動肺炎專家組的工作。

  • In parallel, we continue to develop companion diagnostics with our pharma partners on QIAstat. Next, QIAcuity Digital PCR continue to see steady adoption as customers convert from QPCR and NGS to digital PCR. In '25, cumulative QIAcuity placements exceeded 3,200 systems worldwide.

    同時,我們繼續與製藥合作夥伴在 QIAstat 上開發伴隨診斷。接下來,隨著客戶從 QPCR 和 NGS 轉向數位 PCR,QIAcuity 數位 PCR 繼續穩步普及。2025 年,QIAcuity 系統在全球累積安裝量超過 3,200 套。

  • This reflects continued uptake of digital PCR where higher precision, absolute quantification and more standardized results are required. Our focus remains on expanding the assay portfolio and improving workflows.

    這反映出數位 PCR 技術在需要更高精度、絕對定量和更標準化結果的領域中持續應用。我們將繼續專注於擴大檢測產品組合和改善工作流程。

  • Gene expression remains an important use case for QIAcuity alongside applications such as cell and gene therapy.

    除了細胞和基因治療等應用之外,基因表現仍是 QIAcuity 的重要應用案例。

  • Automation is another key focus with the launch of a nanoplate handling solution codeveloped with Hamilton on the platform. enabling walkway automation and more standardized workflows for regulated environments. Last, Qiagen Digital Insights, where we continue to develop bioinformatics portfolio to ship both research and clinical use. This includes progress with Franklin.

    自動化是另一個重點,該公司與 Hamilton 共同開發了基於該平台的奈米板處理解決方案,實現了通道自動化,並為受監管環境帶來了更標準化的工作流程。最後是 Qiagen Digital Insights,我們將繼續開發生物資訊學產品組合,以滿足研究和臨床應用的需求。這包括與富蘭克林的進展。

  • Following the Genoox acquisition integrated Qiagen's curated knowledge with AI-enhanced workflows to support genetic interpretation and clinical reporting. AI has been embedded across QDI, and we are continuing to support research, data science and commercial solutions by improving workflows, consistency and the use of high-quality genomic content.

    收購 Genoox 後,將 Qiagen 的精選知識與 AI 增強的工作流程相結合,以支持基因解讀和臨床報告。AI 已融入 QDI 的各個方面,我們將繼續透過改善工作流程、一致性和高品質基因組內容的使用來支持研究、數據科學和商業解決方案。

  • For the next two years, our focus is to continue developing at least 14 AI-enabled software solution within DI. We are also preparing to integrate single sale data sets from past Biosciences into the QDI portfolio, connecting single-cell data with downstream analysis to support predictive modeling across research and transnational.

    未來兩年,我們的重點是繼續在數位基礎設施領域開發至少 14 個人工智慧軟體解決方案。我們也準備好將過去生物科學領域的單一銷售資料集整合到 QDI 產品組合中,將單細胞資料與下游分析連接起來,以支援跨研究和跨國領域的預測建模。

  • And now back to Roland for the outlook.

    現在讓我們把目光轉向羅蘭,看看他展望未來。

  • Roland Sackers - Managing Director, Chief Financial Officer, Member of the Executive Board

    Roland Sackers - Managing Director, Chief Financial Officer, Member of the Executive Board

  • Thank you, Thierry. Let me now provide some additional perspectives on our outlook for '26 and for the first quarter. Our ambition remains to deliver solid profitable growth as we continue to navigate a challenging macroeconomic environment.

    謝謝你,蒂埃里。現在讓我再補充一些關於2026年及第一季的展望。我們依然致力於在充滿挑戰的宏觀經濟環境下實現穩健的獲利成長。

  • Against this backdrop, we remain on track toward our '28 ambitions of around 7% core sales CAGR from '24 to '28 and adjusted operating income margin of at least 31%, at least $2 billion of sales from our growth and sustained shareholder returns having already delivered more than $1 billion since '24. For the full year '26, we are initiating an outlook for sales growth of at least 5 percentage point CER and adjusted earnings per share of at least $2.50 at CER.

    在此背景下,我們仍有望實現 2028 年的目標,即 2024 年至 2028 年核心銷售額複合年增長率約為 7%,調整後營業利潤率至少達到 31%,增長帶來的銷售額至少達到 20 億美元,持續的股東回報(自 2024 年以來已超過 10 億美元)也將持續增長。對於 2026 年全年,我們預計銷售額成長至少達到 5 個百分點(以固定匯率計算),調整後每股盈餘至少達到 2.50 美元(以固定匯率計算)。

  • Turning to the first quarter. We expect net sales growth of at least 1% CER compared with sales of $483 million of the first quarter of '25. The growth rate for the first quarter compared to the full year target reflects temporary factors.

    進入第一季。我們預計淨銷售額將比 2025 年第一季的 4.83 億美元成長至少 1%(以固定匯率計算)。第一季成長率與全年目標相比,反映出一些暫時性因素。

  • First, we are absorbing the year-over-year impact from the discontinuation of NeuMoDx and, which represents a headwind of about $10 million or about 2 percentage points in the first quarter. We will see the same impact in the second quarter of '26, but then it rolls off since these products were discontinued in June '25.

    首先,我們正在承受 NeuMoDx 停產帶來的年比影響,這將在第一季造成約 1,000 萬美元或約 2 個百分點的不利影響。我們將在 2026 年第二季看到同樣的衝擊,但之後這種衝擊就會逐漸消失,因為這些產品已在 2025 年 6 月停產。

  • Second, and like others in our industry, we continue to see cautious life science customer spending trends carrying over from '25 into the beginning of '26. We have reflected an estimated impact of about $10 million in the first quarter or about 2 percentage points of growth.

    其次,與業內其他公司一樣,我們繼續看到生命科學客戶謹慎的支出趨勢從 2025 年延續到 2026 年初。我們已反映出第一季約 1000 萬美元的影響,或約 2 個百分點的成長。

  • At the same time, we continue to expect an improvement in the funding environment over the course of the year. And third, QuantiFERON faces a strong comparison to results in the first quarter of 25% when sales was 16% CER and supported by tender activity in the Middle East and Latin America.

    同時,我們仍然預期今年的融資環境會有所改善。第三,QuantiFERON 面臨著與第一季 25% 的業績相比的巨大挑戰,當時銷售額以固定匯率計算增長了 16%,這得益於中東和拉丁美洲的招標活動。

  • As a result, we expect QuantiFERON to grow at a low single-digit CER rate in the first quarter of '26, representing a headwind of about $6 million to $7 million or about 1 percentage point of headwinds through a normalized full year run rate for '26 of about 6% CER growth.

    因此,我們預計 QuantiFERON 在 2026 年第一季將以個位數的 CER 成長率成長,這將對 2026 年全年約 6% 的 CER 成長率造成約 600 萬至 700 萬美元的不利影響,或造成約 1 個百分點的不利影響。

  • Turning to earnings. Our outlook for the first quarter is for adjusted earnings per share of at least $0.54 CER compared to -- with $0.55 in the first quarter of '25. Operational efficiency remains a priority in '26 and continues to support profitability.

    接下來談談收益狀況。我們對第一季的預期是,調整後每股盈餘至少為 0.54 美元(以固定匯率計算),而 2025 年第一季為 0.55 美元。2026年,營運效率仍是首要任務,並將持續支撐獲利能力。

  • At the same time, earnings for the first quarter of '26 are expected to absorb the $0.02 dilutive impact of the past acquisition as well as an adverse impact of about $0.02 from the US tariffs that were implemented later in '25.

    同時,預計 2026 年第一季的收益將吸收過去收購帶來的 0.02 美元稀釋影響,以及 2025 年稍後實施的美國關稅帶來的約 0.02 美元不利影響。

  • For the first half of '26, we currently anticipate sales growth of about $0.02 to $0.03 CER, followed by an acceleration in the second half of the year. The acceleration in the second half reflects various factors, and let me provide a bridge to our full year outlook.

    預計 2026 年上半年銷售額將成長約 0.02 至 0.03 美元(以固定匯率計算),隨後下半年將加速成長。下半年的加速成長反映了多種因素,讓我在此引出我們對全年的展望。

  • As a first point, the comparison impact from the roll-off headwinds from NeuMoDx and contributes about 2 percentage points of incremental growth. New product launches, including the three new instruments as well as new offerings for QIAstat-Dx and QIAcuity are expected to add an additional 2 percentage points of growth.

    首先,NeuMoDx 的下滑帶來的不利影響,對比較結果產生了約 2 個百分點的增量成長。新產品的推出,包括三款新儀器以及 QIAstat-Dx 和 QIAcuity 的新產品,預計將帶來額外的 2 個百分點的成長。

  • As a next point, acceleration year-over-year growth from QuantiFERON starting in the second quarter of '26 is expected to provide about 0.5 percentage point of incremental growth and improving US

    其次,預計自2026年第二季起,QuantiFERON的年成長將加速,帶來約0.5個百分點的增量成長,並改善美國市場。

  • academic and governmental funding trends together with a higher contribution from parts in the second half are expected to add approximately another 0.5 percentage points. Taking together, these factors fully explains the bridge from approximately 1% growth in the first quarter to at least 5% growth for the full year.

    學術界和政府的資金趨勢,加上下半年各部分貢獻的增加,預計將再增加約 0.5 個百分點。綜合以上因素,可以完全解釋為什麼第一季成長率約為 1%,而全年成長率至少達到 5%。

  • Turning to margins.

    轉向邊際效應。

  • We expect adjusted operating income margin to remain at about 29.5% of sales as efficiency gains and broad-based growth are expected to offset margin headwinds of about 160 basis points from the past acquisition, adverse currency movements and tariffs. This underpins our full year '26 target for adjusted EPS of at least $2.50 CER and the step-up from our '25 results.

    我們預計,由於效率提升和全面成長有望抵銷過去收購、不利的匯率波動和關稅帶來的約 160 個基點的利潤率不利影響,調整後的營業利潤率將維持在銷售額的 29.5% 左右。這支撐了我們 2026 年全年調整後每股收益至少達到 2.50 美元(以固定匯率計算)的目標,並比 2025 年的業績有所提升。

  • Let me also provide some perspectives on the currency trends against US dollar. For the full year, our currency expect tailwind of about 1 percentage point on sales and a neutral effect on adjusted EPS results. For the first quarter, we currently expect a tailwind of about 2 percentage to 3 percentage points on sales and a neutral impact on adjusted EPS results.

    我也想就這些貨幣兌美元的走勢提供一些看法。預計全年銷售額將受惠於貨幣匯率的上漲約 1 個百分點,對調整後的每股盈餘 (EPS) 業績影響不大。我們目前預期第一季銷售額將成長約 2% 至 3 個百分點,對調整後每股盈餘的影響為中立。

  • Overall, we have taken a prudent approach in setting our outlook, reflecting current market conditions and known headwinds while positioning Qiagen to continue to rank among the fastest-growing companies in our sector.

    總體而言,我們在製定展望時採取了謹慎的態度,反映了當前的市場狀況和已知的不利因素,同時使 Qiagen 繼續保持在行業內增長最快的公司之列。

  • I would like to now hand back to Thierry.

    現在我想把機會交還給蒂埃里。

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • Thank you, Roland. And before we go to the Q&A, let me quickly summarize our key messages for today. First, looking back on 2025, Qiagen delivered another solid quarter and closed the year with consistent execution across the business.

    謝謝你,羅蘭。在進入問答環節之前,讓我快速總結一下我們今天的主要訊息。首先,回顧 2025 年,凱傑又取得了穩健的季度業績,並在全年業務中保持了持續的執行力。

  • The growth pillars grew at 8% CER and this is among the fastest in our industry. This once again reflects the strength and balance of our portfolio across life sciences and diagnostics.

    成長支柱以固定匯率計算成長了 8%,這是我們行業中最快的成長速度之一。這再次體現了我們在生命科學和診斷領域的產品組合的實力和平衡。

  • At the same time, we remain obviously mindful of our environment. We continue to operate amid macroeconomic uncertainty, cautious capital spending and ongoing volatility, which requires discipline and focus in how we manage the business.

    同時,我們顯然也始終關注著我們的環境。我們繼續在宏觀經濟不確定性、謹慎的資本支出和持續波動的環境下運營,這要求我們在業務管理方面保持自律和專注。

  • Looking ahead, our growth pillars are positioned to continue growing in 2026, supported by a very strong pipeline of new product launches and portfolio additions. While we continue to see a cautious life sciences funding environment and softer capital spending we expect conditions to improve gradually over the course of the year.

    展望未來,在強大的新產品發布和產品組合擴充計畫的支持下,我們的成長支柱預計在 2026 年繼續成長。儘管我們仍看到生命科學領域的融資環境較為謹慎,資本支出也較為疲軟,但我們預期這種情況將在今年內逐步改善。

  • Keep in mind that our outlook for the first half of 2026, is clearly impacted by many base effects from last year, and we are relentless about the contributions ahead from the upcoming new product launches.

    請記住,我們對 2026 年上半年的展望顯然受到去年諸多基數效應的影響,而且我們正全力以赴地關注即將推出的新產品所帶來的貢獻。

  • We expect our growth pillars combined to step up again in '26, targeting growth of around 9% at CER. Sample technologies is targeting sales of around $720 million CER. QuantiFERON, around $535 million. QIAstat around $160 million. QIAcuity around $100 million and QDI around $125 million.

    我們預計 2026 年我們的成長支柱將再次加速,目標是以固定匯率計算實現約 9% 的成長。Sample Technologies 的目標是實現約 7.2 億美元的銷售額。QuantiFERON,約 5.35 億美元。QIAstat 約 1.6 億美元。QIAcuity 預計支出約 1 億美元,QDI 預計支出約 1.25 億美元。

  • As you clearly see, our focus remains on disciplined execution and operational excellence. In 2025, adjusted diluted EPS grew to $2.40 at CER, and we continue to return capital to shareholders. With the completion of the $500 million share repurchase at the beginning of 2026, we delivered on our commitment for solid profitable growth.

    正如您所看到的,我們始終專注於嚴謹的執行和卓越的營運。2025 年,經調整後的稀釋每股盈餘(以固定匯率計算)成長至 2.40 美元,我們將繼續向股東返還資本。隨著 5 億美元的股票回購計畫於 2026 年初完成,我們實現了穩健獲利成長的承諾。

  • Those results are keeping us on track against our 2028 ambitions of about 7% sales CAGR, at least 31% adjusted operating income margin at least $2 billion of sales from our growth pillars and the shareholder returns of at least $1 billion, which, as I just said, we already exceeded. With that, I'd like to thank you again for your attention and hand back to Daniel and the operator for the Q&A session.

    這些成果使我們朝著 2028 年的目標穩步邁進,即銷售額複合年增長率約為 7%,調整後營業利潤率至少達到 31%,增長支柱業務的銷售額至少達到 20 億美元,股東回報至少達到 10 億美元,正如我剛才所說,我們已經超額完成了這些目標。最後,再次感謝大家的關注,現在把答疑環節交還給丹尼爾和接線生。

  • Daniel Wendorff - Vice President of Head of Relations

    Daniel Wendorff - Vice President of Head of Relations

  • Thank you very much, Thierry. Operator, I think we can now go into the Q&A session.

    非常感謝你,蒂埃里。操作員,我想我們現在可以進入問答環節了。

  • Operator

    Operator

  • (Operator Instructions) Tycho Peterson, Jefferies

    (操作說明)泰科·彼得森,傑富瑞

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Hey, thanks. I want to start out on some of the new product launches. QIAcuity, QIAstat, adding 200 basis points to growth in the back half of the year. Maybe just give us a little more color on the products? Is this about new markets or deeper penetration? And what gives you confidence that will contribute to growth out of the gate?

    嘿,謝謝。我想先從一些新產品的發布開始說起。QIAcuity 和 QIAstat 為下半年的成長貢獻了 200 個基點。或許可以再多介紹一下產品?這是為了開拓新市場還是深化市場滲透?是什麼讓你充滿信心,以便在起步階段就取得成長?

  • And then on QIAcuity, help us bridge to the $250 million target by 2028 because you have missed your targets there in the last couple of years. So talk about what you think really gets you to that target by 2028? And then just one follow-up on QuantiFERON, the assumptions for the back half of the year bridge. I think you previously said growth targets would include competitive entry. Is that still baked in and by how much?

    然後,關於 QIAcuity,請幫助我們實現到 2028 年 2.5 億美元的目標,因為你們在過去幾年中沒有實現該目標。那麼,請談談你認為到 2028 年真正能幫助你實現目標的因素是什麼?然後,關於 QuantiFERON,還有一個後續問題,即下半年過渡期的假設。我認為你之前說過,成長目標將包括競爭性准入。那層味道還留在烤箱裡嗎?還保留了多少?

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • Thank you, Tycho, and I will try to make sure that I'm not forgetting any of your questions. On the new products and the impact of at least 2% extra growth from H2 to compared to H1 of '26.

    謝謝你,泰科,我會盡量確保不會遺漏你的任何問題。關於新產品以及與 2026 年上半年相比,下半年至少額外成長 2% 的影響。

  • The way you need to see it is that at least three of those new launches are opening completely new markets from Qiagen. Of course, the new panel of QIAstat, the blood culture panel is opening new segment of customers, new needs. So it's an add-on.

    你應該這樣理解:至少有三款新產品的推出,為凱傑公司開拓了一個全新的市場。當然,QIAstat 的新型血液培養檢測板正在開拓新的客戶群,滿足新的需求。所以它是附加元件。

  • In Sample tech, QlAsprint marks the entry of Qiagen into very high sample technologies, where we are not at the moment, therefore, new market. calamine is offering or will offer automation for low throughput labs or very small volume research, new markets.

    在樣品技術領域,QlAsprint標誌著Qiagen正式進軍超高精度樣品技術領域,這是我們目前尚未涉足的領域,因此也是一個全新的市場。 Calamine目前或未來將為低通量實驗室或小批量研究提供自動化解決方案,同樣也是新的市場。

  • So you can see that it's justified and realistic to add growth in the second half of the year because of those impact. QIAsymphony Connect will be not only upgraded QIAsymphony, but probably also convince other customers to adopt this technology. So that's why we are confident in this number.

    因此,可以看出,考慮到這些影響,在下半年增加成長是合理且現實的。QIAsymphony Connect 不僅是 QIAsymphony 的升級,而且很可能會說服其他客戶採用這項技術。所以這就是我們對這個數字充滿信心的原因。

  • On QIAcuity, you are perfectly right, Tycho, over the last two years because our sales on digital PCR, are mainly directed at the moment in research and academia, we have disclosed that we have been impacted by a more sluggish environment of capital expenses in research and academia.

    關於 QIAcuity,Tycho,你說得完全正確。過去兩年,由於我們的數位 PCR 銷售主要面向科學研究和學術界,我們已經揭露,科學研究和學術界的資本支出環境較為疲軟,這對我們造成了影響。

  • So that created a bit of delay in revenues coming from instrumentation from Digital Pass. The consumables have been good for the last three years, we systematically grew at double digits. But in three months, were a bit below our expectation. But again, what are we talking about here?

    因此,來自 Digital Pass 儀器的收入出現了一些延遲。過去三年,消耗品市場表現良好,我們實現了兩位數的穩定成長。但三個月後,結果略低於我們的預期。但是,我們到底在討論什麼呢?

  • When we see -- when we say below our expectation, if I take 2025 as an example, we still put more than 500 new QIAcuity on the market. If you look at Q4, we put more than 100 systems in Q4, 100 new QIAcuity. Those systems will obviously generate consumables tomorrow.

    當我們看到——當我們說低於預期時,以 2025 年為例,我們仍然向市場投放了 500 多台新的 QIAcuity 設備。如果你看一下第四季度,我們在第四季度安裝了 100 多個系統,100 個全新的 QIAcuity 系統。這些系統顯然會在明天產生消耗品。

  • So we have indeed given a target of $250 million of revenues by '28 for Digital PCR at Qiagen. We might have a slight delay because of the sluggish capital expense environment, but what is important to us is that we continue to grow, we capture new market and we grow consumables at double digit while still placing a significant number of instruments every year.

    因此,我們確實為 Qiagen 的數位 PCR 業務設定了 2028 年實現 2.5 億美元收入的目標。由於資本支出環境疲軟,我們可能會稍有延遲,但對我們來說重要的是,我們要繼續成長,開拓新市場,並以兩位數的速度增長耗材,同時每年仍然投放大量儀器。

  • Now for QuantiFERON. We explained the profile of the growth for '26. H1 is impacted by base effect coming by tenders and significant contract in Q4 of '24 and Q1 of '25. You will see QuantiFERON picking up in Q2. And obviously, those base effects will progressively disappear.

    接下來是 QuantiFERON。我們解釋了 2026 年的成長概況。上半年業績受到 2024 年第四季和 2025 年第一季招標和重大合約帶來的基數效應的影響。QuantiFERON 將在第二季迎來成長。顯然,這些基礎效應會逐漸消失。

  • And you'll see QuantiFERON accelerating to achieve probably above 6% growth, let's say, between 6% and 7% growth in 2027 -- in '26, I'm sorry, which is perfectly aligned with the target that we gave during our Capital Market Day in June '24, QuantiFERON will be $600 million revenues by 2028.

    您將會看到 QuantiFERON 加速成長,預計到 2027 年(抱歉,應該是 2026 年)將實現 6% 以上的成長,比如說 6% 到 7% 的成長。這與我們 2024 年 6 月資本市場日上給出的目標完全一致,QuantiFERON 到 2028 年的收入將達到 6 億美元。

  • Operator

    Operator

  • Jack Meehan, Nephron.

    Jack Meehan,腎臟病。

  • Jack Meehan - Equity Analyst

    Jack Meehan - Equity Analyst

  • Thank you. Hi everyone. Thierry, I wanted to get your thoughts. There were headlines a few weeks ago around Qiagen as a potential deal target. Again, I was wondering what comments, if any, you can share on that.

    謝謝。大家好。蒂埃里,我想聽聽你的想法。幾週前,曾有新聞報導 Qiagen 可能成為收購目標。我想再次詢問一下,您對此有何評論(如果有的話)。

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • Thanks for the question, Jack, and I was expecting a question on this. I mean it's fair to say that -- our market is still and will still going through consolidation.

    謝謝你的提問,傑克,我正料到你會問這個問題。我的意思是,可以公平地說——我們的市場現在仍在經歷整合,而且還會繼續經歷整合。

  • That's point number one. At the same time, Qiagen is delivering and focusing on delivering on our solid plan for the coming years, the plan that we disclosed in New York in June '24, 7% CAGR on the top line, at least 31% EBIT margin, $2 billion from our pillars of growth. So this is where we are focusing.

    這是第一點。同時,凱傑正在推進並專注於推進我們未來幾年的穩健計劃,該計劃我們在 2024 年 6 月於紐約公佈,目標是營收年複合增長率達到 7%,息稅前利潤率至少達到 31%,並從我們的成長支柱中獲得 20 億美元的收入。所以,這就是我們關注的重點。

  • At the same time, we do not comment on rumors we are always open for discussion that could create value for shareholders and I cannot say more at this stage.

    同時,我們不對傳言發表評論,我們始終樂於進行可能為股東創造價值的討論,但現階段我無法透露更多資訊。

  • Jack Meehan - Equity Analyst

    Jack Meehan - Equity Analyst

  • Understood. And appreciate the execution has been really solid, and you still have your hand firmly on the wheel but also did want to ask about the CEO succession search. Just was wondering when you think might have an update on that?

    明白了。我很欣賞目前的執行情況非常穩健,您仍然牢牢掌控著局面,但我也想問一下關於CEO繼任者遴選的問題。想問您大概什麼時候會有關於此事的最新消息?

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • What is important for the Board and for the company is to find the best person for the job. So we have a search ongoing, as we said in Q4 of '25, this is both an external and internal search. It's advancing very well, but we need to take the necessary time once again to find the best person for the job.

    對董事會和公司而言,最重要的是找到最適合這份工作的人。所以,正如我們在 2025 年第四季度所說,我們正在進行一項搜索,這項搜索既包括外部搜索,也包括內部搜索。進展非常順利,但我們需要再次花必要的時間找到最適合這份工作的人。

  • In the meantime, we do have a management fully dedicated to Qiagen. It's not only theory, it's the entire relegate committee and also 5,700 of Qiagen all over the world. We will obviously update you as we can progress.

    同時,我們確實有一個完全專注於 Qiagen 的管理團隊。這不僅僅是理論,而是整個代表委員會以及遍布全球的 5700 名 Qiagen 員工。我們會隨時向您報告進度。

  • Operator

    Operator

  • Casey Woodring, JPMorgan.

    Casey Woodring,摩根大通。

  • Casey Woodring - Analyst

    Casey Woodring - Analyst

  • Wanted to ask on the margin expansion piece. The bridge to 2026 didn't seem to include any operating margin improvement this year outside of the efficiency program, which will part in tariff headwinds unless I'm misinterpreting your comments there. So maybe just can you walk us through how you're thinking about organic operating leverage across the business and how some of the new product volume is expected to contribute to the bottom line this year?

    想問一下關於邊際效益提升的問題。到 2026 年的過渡計劃似乎不包括今年效率提升計劃之外的任何營運利潤率改善,除非我誤解了您的評論,否則該計劃將受到關稅不利因素的影響。那麼,您能否詳細介紹一下您是如何考慮整個業務的有機運營槓桿作用的,以及預計今年一些新產品銷售將如何為公司盈利做出貢獻?

  • Roland Sackers - Managing Director, Chief Financial Officer, Member of the Executive Board

    Roland Sackers - Managing Director, Chief Financial Officer, Member of the Executive Board

  • As, again, I do think actually that '26 will be another significant margin improvement year for Qiagen because I think it's really fair to say that we do expect we announced headwinds from the acquisitions of Parse. As you know, that is an acquisition where we're doubling up on the R&D -- doubling down on the R&D investment.

    而且,我確實認為 2026 年將是 Qiagen 利潤率大幅提升的一年,因為我認為可以公平地說,我們預計收購 Parse 會帶來一些不利影響。如您所知,這是我們將研發投入加倍的收購——我們將加大研發投資。

  • So there's clearly a certain dilution for us to expect for this year, and that is around 100 basis points for 2026. In addition to that, we have a combined headwind again also from tariffs and FX in '26. So there will be a net margin improvement -- or gross margin improvement for around about 160 basis points for this year, which again will be compensated, as I said, from pass and tariffs and expected currency headwinds.

    因此,我們顯然可以預期今年會出現一定的稀釋,而到 2026 年,稀釋幅度約為 100 個基點。除此之外,2026 年我們還將面臨關稅和外匯方面的雙重不利因素。因此,今年的淨利潤率(或毛利率)將提高約 160 個基點,正如我所說,這將被通行費、關稅以及預期的匯率不利因素所抵消。

  • So 160 basis points, how does this break down? A larger part actually this year comes, and we talked about that in the past, from gross margin improvement. I would say probably somewhere between 75 and plus basis points in '26 comes from gross margin improvement.

    那麼,160個基點,這具體是怎麼構成的呢?今年更大的成長其實來自於毛利率的提高,我們之前也討論過這一點。我認為 2026 年毛利率的提高可能會帶來 75 個基點以上的成長。

  • Have in mind, you will see an acceleration, quite significant acceleration in Sample. And clearly, Sample preparation is also 1 of the product groups, which has a significant gross margin contribution to Qiagen.

    請注意,您將會看到樣本出現加速,而且是相當大的加速。顯然,樣品製備也是 Qiagen 毛利率貢獻較大的產品類別之一。

  • So that should be helpful. And in addition to that, we still continue to see outstanding growth trend around QIAstat. And you also know that we in the past talked about that we're still running an underutilization in terms of production utilization for QIAstat.

    這應該會有幫助。除此之外,我們仍然看到 QIAstat 呈現出顯著的成長趨勢。而且您也知道,我們過去曾討論過,QIAstat 的生產利用率仍然不足。

  • So also here, better utilization will drive gross margin improvement. Last but not least, we still have ongoing 40 QIA efficiency program on the operational expense side, they all will contribute not only in '26 also beyond.

    因此,提高資源利用率也將推動毛利率的提高。最後但同樣重要的是,我們在營運費用方面仍然有 40 個 QIA 效率提升計劃正在進行中,它們不僅將在 2026 年做出貢獻,而且在未來也會做出貢獻。

  • So again, we expect margin improvement this year. We expect to continue that in '27 '28. And as said in his remarks, we clearly do believe we will see a significant step up north of the 31%, which was announced for '28.

    因此,我們預計今年的利潤率將有所提高。我們預計在 2027 年和 2028 年將繼續保持這一勢頭。正如他在演講中所說,我們顯然相信我們將看到超過 31% 的顯著進步,而 31% 是 2028 年宣布的目標。

  • Casey Woodring - Analyst

    Casey Woodring - Analyst

  • Okay, we'll leave it there.

    好的,我們就說到這裡吧。

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Aisyah Noor, Morgan Stanley.

    艾莎‧努爾,摩根士丹利。

  • Aisyah Noor - Analyst

    Aisyah Noor - Analyst

  • My one question is on China. So can you confirm if you're exposed to VBP or any large tender renewals that we should be aware about? And what's the kind of growth outlook embedded in your guidance?

    我的問題是關於中國的。所以,您能否確認一下,貴公司是否參與了基於價值的採購(VBP)項目,或者是否有任何我們應該注意的大型招標續期項目?您的指導意見中體現了怎樣的成長前景?

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • Thanks for the question. Aisyah, we keep the same attitude and consideration towards China. As we have said for the last three years, it's not significant in our revenues anymore. Our exposure is 4% to China. It's a large market.

    謝謝你的提問。艾莎,我們對中國仍保持同樣的態度和考慮。正如我們過去三年一直強調的那樣,它對我們的收入來說已經不再重要了。我們在中國的投資佔比為4%。這是一個很大的市場。

  • It's too large of a market to be ignored. At the same time, it's too specific and too politically driven as a market to make it an investment case. We are not specifically more impacted by VBP because VBP has been implemented across molecular solution at least for the last three years in China. So it's nothing new for us. Last year was negative.

    這是一個不容忽視的龐大市場。同時,作為一個市場,它過於特殊,且受政治因素驅動,因此不具備投資價值。我們並沒有受到 VBP 的特別大影響,因為 VBP 至少在中國已經實施了三年之久。所以這對我們來說並不新鮮。去年業績為負。

  • We continue to think that China will be between low single digit to negative to a very base flat, and we do not expect in the current political situation, economic situation and market situation of China to see a return of growth in the visible future. But again, our exposure is very limited, as I said, 4% of sales.

    我們仍然認為中國經濟成長將徘徊在個位數低點到負成長,甚至基本持平,而且在目前中國的政治、經濟和市場情勢下,我們預計在可預見的未來不會出現成長復甦。但正如我所說,我們的市佔率非常有限,僅佔銷售額的 4%。

  • Operator

    Operator

  • Odysseas Manesiotis, BNP Paribas.

    奧德賽馬內西奧蒂斯,法國巴黎銀行。

  • Odysseas Manesiotis - Analyst

    Odysseas Manesiotis - Analyst

  • Firstly, on QIAstat. You finally have a complete high-volume platform during what seems to be a material year for replacing such instruments. Is it fair to assume that you do much better than the 600 placements you did in '26 -- in '25?

    首先,關於 QIAstat。在今年似乎是更換這類儀器的重要一年,您終於擁有了一個完整的、大容量的平台。是否可以合理地假設,你在 2025 年的表現比 2026 年的 600 個就業機會好得多?

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • Well, I appreciate that always want more, but more than 600 placements in 2025, it's already a good performance. So I prefer to leave it like this. We grew at 25% for Q4, we grew at much more than double digit for '25. We gave you an objective of more than $160 million for '26, which shows again a double-digit growth. We are a solid number two in this market.

    我知道大家總是想要更多,但是到 2025 年能達到 600 多個職位,這已經是一個不錯的成績了。所以我比較傾向於維持現狀。第四季我們成長了 25%,2025 年全年成長遠超兩位數。我們為你們設定了 2026 年超過 1.6 億美元的目標,這再次顯示了兩位數的成長。我們在這個市場中穩居第二。

  • This is exactly what we wanted to achieve. And if we can beat our objective or new placement, we will do it. But let's execute first on the $160 million. Let's execute on the product launches on the market penetration, and that will be already good.

    這正是我們想要達到的效果。如果我們能夠超越目標或達到新的排名,我們就會做到。但我們先來執行這1.6億美元的計畫。讓我們著手進行產品上市,提升市場滲透率,這就已經很不錯了。

  • Odysseas Manesiotis - Analyst

    Odysseas Manesiotis - Analyst

  • And a follow-up on QuantiFERON. Could you give us of additional color on the Q1 guidance here? I mean, is there any price component to your conservativeness there? And how exactly were these one-off tenders, given the low shelf life of the kit?

    還有關於 QuantiFERON 的後續報導。您能否就第一季業績指引提供更多細節?我的意思是,你的保守態度是否與價格因素有關?考慮到套件的保質期很短,這些一次性的補給品究竟是如何運作的?

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • Yes. I think it's not a question of sales life. It's a fair question, but it's just a comparison quarter-on-quarter on deals that we have been able to include in ourselves. It's a base effect. If you look at Qiagen recent communication on QuantiFERON

    是的。我認為這與銷售生涯無關。這是一個合理的問題,但這只是我們能夠納入統計的交易的季度間比較。這是一個基礎效果。如果你看看Qiagen最近關於QuantiFERON的公告,你會發現它非常出色。

  • it did include over the last 3 years, some press releases, some time of significant tenders in Middle East. The contract with Oman was one of them. In Latin America, the contract in Brazil was another 1 of them. So those are creating a base impact compared to Q1 2026 because of their date of signature or renewal. As Roland explained during his comments, growth of QuantiFERON for Q1 2025 was close to 16%.

    在過去三年裡,其中確實包括一些新聞稿,以及中東地區的一些重大招標項目。與阿曼簽訂的合約就是其中之一。在拉丁美洲,巴西的那份合約也是其中之一。因此,由於簽署或續約日期的原因,這些因素會對 2026 年第一季產生基本影響。正如羅蘭在評論中解釋的那樣,QuantiFERON 在 2025 年第一季的成長接近 16%。

  • We need to compare this with a normalized growth of QuantiFERON over the year, which is 10%. In other word, we grew in Q1 of '25, 6 points above the normal growth of Qiagen. It creates necessarily a base impact. This is not a conservative guidance. It's just a realistic guidance.

    我們需要將此與 QuantiFERON 一年的正常成長率(10%)進行比較。換句話說,我們在 2025 年第一季實現了成長,比 Qiagen 的正常成長率高出 6 個百分點。它必然會產生基礎性影響。這並非保守的指導。這只是一個務實的指導意見。

  • Regarding prices, we were very clear when we issued the guidance for QuantiFERON early '25. We know that competition will increase on that market. We factor that in our number $600 million for 2028.

    關於價格,我們在 2025 年初發布 QuantiFERON 指導價時已經非常明確地說明了這一點。我們知道,該市場的競爭將會加劇。我們把這一點考慮在內,預計 2028 年將達到 6 億美元。

  • And we always said that our plan commercially is to move even more customers to contract. This is good for the business. This is good for the franchise. If this sometimes goes with a bit of pricing flexibility, it's a good thing to do.

    我們一直都說,我們的商業計劃是讓更多客戶簽訂合約。這對公司來說是好事。這對系列作品來說是好事。如果這能帶來一些價格上的彈性,那是一件好事。

  • Operator

    Operator

  • Michael Ryskin, Bank of America.

    邁克爾·里斯金,美國銀行。

  • Michael Ryskin - Analyst

    Michael Ryskin - Analyst

  • Great, thanks for taking the question, guys. I want to ask a little bit more in the 1Q outlook outside of QuantiFERON. You talked about some of the moving pieces there in terms of the comps, in terms of the new modes shutdown, things like that. I want to dive into your expectations for end markets. You had some comments on you expect end market improvement as you go through the year.

    太好了,謝謝各位回答這個問題。我想就 QuantiFERON 以外的 1Q 展望再多問一些問題。你談到了一些變動因素,例如比賽安排、新模式關閉等等。我想深入了解您對終端市場的期望。您曾表示,您預計終端市場將在今年內有所改善。

  • But maybe if you could just expand on that a little bit of how much of that is built into 1Q specifically, maybe as far as US government shutdown or broader markets in general? And just what's the degree of improvement you're embedding as you go through the year to sort of like hit that back half ramp?

    但您能否再詳細解釋一下,具體來說,第一季有多少因素被納入考量,例如美國政府停擺或更廣泛的市場狀況?那麼,為了在下半年取得更好的成績,你在這一年中究竟取得了多大的進步呢?

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • So the first comment, Michael, is that the overall market, if I look at some of our main competitors' recent earning calls, we see that they are in the same ballpark of guidance for most of them, not to say all of them. It is clear, and we already said that last year that if we consider the funding environment especially for Research and Academia labs and especially in the US, we believe that the situation is better now than it was 6 months ago. Why? Because 6 months ago, most of the comments were targeting a significant decrease of budgets like NIH, for example. Now we know that we are going to be probably seeing a slight increase in '26 of the NIH budget, let's say, max around 1%.

    邁克爾,首先我想說的是,就整體市場而言,如果我看一下我們一些主要競爭對手最近的盈利電話會議,我們會發現他們中的大多數(甚至不是所有)的業績預期都大致相同。很明顯,我們去年就說過,如果我們考慮資助環境,特別是針對研究和學術實驗室的資助環境,尤其是在美國,我們認為現在的情況比6個月前好。為什麼?因為6個月前,大多數評論都針對大幅削減預算,例如美國國立衛生研究院(NIH)的預算。現在我們知道,2026 年美國國立衛生研究院的預算可能會略有增加,比方說最多增加 1%。

  • This is good for the business. At the same time, we said today that we believe that many research and academia lab are still in a kind of wait-and-see attitude. Once they get more visibility, we believe and it's embedded partially in our H2 expectation, that capital expense, especially in research and academia will improve because they will have more visibility. we think that it's fair to assume that progressively throughout 2026, the total market can come back to a growth of mid-single digits.

    這對公司來說是好事。同時,我們今天表示,我們認為許多研究和學術實驗室仍然處於一種觀望態度。我們相信,一旦這些領域獲得更高的知名度(這部分也體現在我們的下半年預期中),資本支出,尤其是在研發和學術領域的支出,將會改善,因為它們將獲得更多關注。我們認為,可以合理地假設,到2026年,整個市場將逐步恢復到中等個位數的成長。

  • Michael Ryskin - Analyst

    Michael Ryskin - Analyst

  • Okay. That's helpful. And then maybe I can dig into Sample tech a little bit in the slides. I think you called out a $720 million target for 2026. Just to confirm, that includes part contribution in it of about $40 million.

    好的。那很有幫助。然後我或許可以在幻燈片中稍微深入探討 Sample 技術。我認為你提出的2026年目標是7.2億美元。確認一下,這其中包含約 4,000 萬美元的部分出資。

  • And then just confirming that. And then the second part of that question would be just how much of that do you expect to be contribution from some of those new automation solutions in Sample tech. Is that a meaningful contributor to 2026 in that part of the portfolio? Or is that just going to take a little bit longer to ramp?

    然後只是確認一下。那麼問題的第二部分就是,你預期 Sample Tech 的一些新的自動化解決方案可以做出多大的貢獻。這是否對投資組合中該部分在 2026 年的表現做出了有意義的貢獻?或者說,這只是需要更長的時間才能達到目標?

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • So you're perfectly right for your numbers. We said $720 million total sample tech. It includes indeed around $40 million contribution from parts. And as we discussed you and I yesterday, past contribution will be higher if you compare H1 to H2 for parts, we are probably at 40% for H1 and 60% for H2 in terms of weight in their revenues. So you're perfectly right on that.

    所以你的數字完全正確。我們說總共耗資7.2億美元用於樣品技術。這其中確實包括來自零件的約 4000 萬美元的投入。正如我們昨天討論的那樣,如果將上半年與下半年進行比較,零件的過去貢獻會更高,上半年零件的貢獻可能達到 40%,下半年零件的貢獻可能達到 60%。所以你在這一點上完全正確。

  • Now if you consider the new launches, QIAsymphony Connect, QIAsprint Connect and QIAmini, they are fully embedded in the 2% extra growth coming from the new products that we are planning H2 to H1.

    現在,如果你考慮一下新推出的產品,QIAsymphony Connect、QIAsprint Connect 和 QIAmini,它們完全融入了我們計劃在下半年到上半年推出的新產品所帶來的 2% 的額外增長中。

  • Operator

    Operator

  • [Kavvia Deshpande, UBS].

    [Kavvia Deshpande,瑞銀集團]

  • Unidentified Participant

    Unidentified Participant

  • Good afternoon. Thank you for taking my questions. Just a couple on QIAstat, please. So firstly, on the guidance for 2026. Is there anything you might be able to share on what you're assuming in that guide for the US respiratory in 2026? And then secondly, I think you shared a couple of years ago, that at the point of your last CMD, over 50% of QIAstat customers were using more than 2 panels.

    午安.謝謝您回答我的問題。請用QIAstat軟體測試幾個問題。首先,關於 2026 年的指導方針。您能否分享一下您在2026年美國呼吸道疾病指引中所做的假設?其次,我想您幾年前分享過,在您上次的 CMD 會議上,超過 50% 的 QIAstat 客戶正在使用 2 個以上的面板。

  • Would you have any update on this, it would be good to get that just given you've done a lot of menu expansion since then?

    請問這方面有什麼最新進展嗎?考慮到你們之後對菜單進行了很多擴展,很想知道這方面的資訊。

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • That was our first question. I think we have seen that, again, the respiratory season was significant from December '25 to probably now, we'll see what is going to happen in the coming weeks. You perfectly, I believe that there are harsh winter conditions in the US as we speak, but it's too early to say. What I can tell you is that I believe that relator issues will remain significant for the years to come.

    這是我們提出的第一個問題。我認為我們已經看到,從 2025 年 12 月到現在,呼吸道疾病流行季非常顯著,我們將看看未來幾週會發生什麼。你說得完全正確,我相信現在美國正經歷嚴寒的冬季,但現在下結論還為時過早。我可以告訴你的是,我認為人際關係問題在未來幾年仍將十分重要。

  • And that's why the respiratory panel on syndromic like QIAstat are so important. I think people are more aware, they are more aware of flu, whether it's A&B, RSV, obviously, COVID or other respiratory pathogen. So I believe that it's going to become a well-established panel and testing for the years to that's why it's key to have this panel.

    這就是為什麼像 QIAstat 這樣的綜合徵檢測中的呼吸系統檢測項目如此重要的原因。我認為人們的意識提高了,他們對流感,無論是甲型和乙型流感、呼吸道合胞病毒(RSV),還是新冠病毒或其他呼吸道病原體,都有了更高的認識。所以我相信它會成為一個成熟的專家小組,並經過多年的測試,這就是為什麼擁有這個專家小組至關重要。

  • And as you know, in the US, not only we have it in a long format, large number of pathogen, but we have it also in a short format more reduced number of pathogen. So to your second part of your question, what's the proportion of customers using more than one panel.

    如您所知,在美國,我們不僅有病原體數量較多的長格式病毒,還有病原體數量較少的短格式病毒。那麼,對於你問題的第二部分,使用多個面板的客戶比例是多少?

  • It's clear that the 50% continues to increase because that's the relevance of adding panel consequently year after year. And as you know, those panels are very coherent they address mostly infacious diseases laboratories. So yes, this number is improving as well.

    很明顯,50% 的比例持續成長,因為逐年增加小組的重要性就在於此。如您所知,這些小組非常連貫,他們主要針對臭名昭著的疾病實驗室。是的,這個數字也在改善。

  • Unidentified Participant

    Unidentified Participant

  • Thank you. Perfect, thank you very much.

    謝謝。太好了,非常感謝。

  • Operator

    Operator

  • Harry Gillis, Berenberg.

    哈里·吉利斯,貝倫貝格。

  • Harry Gillis - Equity Analyst

    Harry Gillis - Equity Analyst

  • Harry GillisAnalyst

    哈里·吉利斯分析師

  • I have two on the midterm guidance. Could you just confirm whether your target for 7% sales growth through to '28 or the $2 billion from your growth pillars stands excluding the contribution of past. And then secondly, you've previously talked about being well ahead of your 31% margin target, but I noticed you haven't really talked about that recently.

    我有兩個關於期中考指導的問題。請您確認一下,您設定的 2028 年達到 7% 銷售成長的目標,或是您提出的成長支柱帶來的 20 億美元收入目標,是否不包括過去的貢獻。其次,您之前曾說過已經遠遠超過了 31% 的利潤率目標,但我注意到您最近並沒有真正談到這一點。

  • And obviously, you talked about 180 basis points of negative FX impact on tariffs over this year and over '25 and '26. Are you still well ahead of this target despite these headwinds? Or should we now assume that's not the case?

    顯然,您談到了今年以及 2025 年和 2026 年匯率對關稅的負面影響達到 180 個基點。儘管面臨這些不利因素,你仍然遠遠領先這個目標嗎?或者我們現在應該假設情況並非如此?

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • So we mentioned that, and I will also ask Roland to chime in at a point first of all, to your first question, the 7% CAGR. We gave that CAGR in June of 2024 in our CMD Capital Market Day in New York. You will agree with us that since 2024, the economic environment have become even more volatile, tariffs, volatility in currency evolutions geopolitical instability, funding difficulties for research and academia. Confronted with those difficult and volatile market condition, this is the role of management to take the necessary capital allocation to defend our growth profiles. And this is perfectly what is behind the acquisition of companies like Genoox and Parse, fully synergistic with our portfolio, accretive to our top line and financially accretive in a reasonable time frame.

    所以我們提到了這一點,我還要請羅蘭先就你的第一個問題,7% 的複合年增長率,發表一下看法。我們在紐約舉行的 CMD 資本市場日上給出了 2024 年 6 月的複合年增長率。您絕對同意我們的觀點,自 2024 年以來,經濟環境變得更加動盪,關稅、貨幣走勢波動、地緣政治不穩定、科學研究和學術界資金困難。面對如此艱難且動盪的市場環境,管理階層的職責就是進行必要的資本配置,以捍衛我們的成長前景。這正是我們收購 Genoox 和 Parse 等公司的原因所在,它們與我們的投資組合完全具有協同效應,能夠增加我們的收入,並在合理的時間範圍內帶來財務收益。

  • So because our environment has worsened, it's fair to say that the 7% now fully include also the recent acquisition. If the market improves quicker, we might even beat that. But at the moment, let's focus and execute on the 7% all in. To the second question, Roland alluded to it, and I will also invite him to give his opinion. We believe we can beat the 31%.

    因此,由於我們的環境惡化,可以說,現在的 7% 也完全包含了最近的收購。如果市場好轉速度更快,我們甚至有可能超越這個目標。但目前,讓我們集中精力,全力以赴完成這7%的目標。對於第二個問題,羅蘭已經有所提及,我也會請他發表一下意見。我們相信我們能戰勝31%。

  • At the same time, we say the market is still difficult around us. So let's see what could be a new guidance analysing different factors before we come to the market. Roland, on this point?

    同時,我們認為我們周圍的市場依然充滿挑戰。那麼,讓我們在進入市場之前,先透過分析各種因素,看看可能會有哪些新的指導意見。羅蘭,你對此有何看法?

  • Roland Sackers - Managing Director, Chief Financial Officer, Member of the Executive Board

    Roland Sackers - Managing Director, Chief Financial Officer, Member of the Executive Board

  • Yes. And again, just to give you some further thoughts to that. Again, as I said before, we clearly do expect that the growth in '26 is particularly driven by a very strong growth of our pillars of growth pillars of growth going to grow 9%. Same is going into high single-digit area. QIAstat nice significantly double-digit.

    是的。最後,我再補充一些想法。正如我之前所說,我們顯然預計 2026 年的成長將主要由我們成長支柱的強勁成長推動,成長支柱將達到 9%。同樣也進入了個位數高位區間。QIAstat 表現良好,顯著達到兩位數。

  • QIAcuity, significantly double-digit. QDI double digit as well. This is a high-margin product for us. So we will see an impact here as well. I do think, and again, also just looking at '25, it's a proof of evidence, right?

    QIAcuity,顯著提高到兩位數。QDI 也達到了兩位數。這是一款利潤率很高的產品。所以我們也會看到這方面的影響。我確實認為,而且再看看 25 年的數據,這本身就是證據,對吧?

  • Sorry that we didn't know that the US is implementing tariffs. But if I exclude that and again, putting currency movement to the side, we gave out a target of $150 million, and we were achieving $200 million. Again, we were not -- just for a single year, that's a significant improvement. We're not standing still this year.

    很抱歉我們不知道美國正在實施關稅。但如果我排除這一點,並且再次將匯率波動放在一邊,我們設定的目標是 1.5 億美元,而我們實現了 2 億美元。再說一遍,我們沒有——僅僅一年時間,這已經是一個很大的進步了。今年我們不會停滯不前。

  • And I'm quite sure that we have for the operational efficiency program, a lot of things which we still can move. So it's not that we have to generate it. It's about execution. And I do think that is well that way. So yes, there will be something north of 31%.

    我非常肯定,在營運效率提升計畫方面,我們還有很多事情可以推進。所以並不是說我們必須去生成它。關鍵在於執行。而且我也認為那樣做很好。所以,是的,會有高於 31% 的數值。

  • I do think it's fair that also to say that we will take the time to announce that because alluding out -- we're in a management transition here. It doesn't mean that the guide the numbers are going to change, but I'd say it's also fair that whoever comes in has to review the number and has the opportunity to review this number and then we go to the market.

    我認為公平起見,我們也要花時間宣布此事,因為——我們正處於管理層過渡期。這並不意味著指導方針中的數字會改變,但我認為公平起見,任何接手的人都必須審查這些數字,並有機會審查這些數字,然後我們再進入市場。

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • Understood, thank you.

    明白了,謝謝。

  • Operator

    Operator

  • Dan Brennan, TD Cowen.

    丹·布倫南,TD Cowen。

  • Daniel Brennan - Analyst

    Daniel Brennan - Analyst

  • Great, thank you. Thanks for the questions, Terry and Roland.

    太好了,謝謝。謝謝Terry和Roland的提問。

  • Maybe just first one, just back to QuantiFERON, if you don't mind. Just on the pricing comment Thierry, has this been consistent with what's been happening in the market over the last couple of years? Or is this kind of more of a newer strategy just to try to lock in some customers, maybe making some price concessions. Just wondering if you can kind of elaborate on that.

    或許就第一個吧,再用一次 QuantiFERON,如果你不介意的話。關於定價方面,Thierry,這與過去幾年市場的發展趨勢一致嗎?或者這只是一種較新的策略,旨在鎖定一些客戶,或許會做出一些價格讓步。想問您能否詳細解釋一下。

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • No, no, it's not a new strategy then. We disclosed that very transparently more than a year ago. We see an evolution of competition, and we need to fight also to make sure that we can move an already important base of customers who are -- that are in -- on a purely annual contract to more customers on contracts. So it's always a negotiation. We just disclosed last year that we need to be ready also to make some concessions.

    不,不,那這並不是什麼新策略。一年多前,我們就非常透明地揭露了這一點。我們看到競爭格局正在演變,我們也需要努力爭取將目前已相當重要的、僅簽訂年度合約的客戶群,轉變為簽訂長期合約的客戶群。所以這始終是一場談判。我們去年已經透露,我們也需要做好一些讓步的準備。

  • But if it secures the deal for two or three years more, I think those are interesting concession. Obviously, they have to be reasonable. What I can guarantee you then is that overall, we continue to pass price increase every year on QuantiFERON as well. So if you look at the performance on pricing 2025 for QuantiFERON, it was positive. I was just saying that when it's necessary, we need to be flexible.

    但如果這能確保協議再延長兩三年,我認為這些讓步很有意思。顯然,他們必須講道理。我可以向你們保證的是,總體而言,我們每年都會繼續提高 QuantiFERON 的價格。因此,如果你看一下 QuantiFERON 2025 年的定價表現,結果是正面的。我只是想說,必要時我們需要靈活變通。

  • That's it.

    就是這樣。

  • Daniel Brennan - Analyst

    Daniel Brennan - Analyst

  • Terrific. And then maybe just a follow-up. I know there was a question earlier backed on like strategic landscape, things like that, which I'm sure you're limited in what you could say. But maybe can you just speak to a little bit the market environment. You've been delivering on your plans and kind of ahead of plans in some cases for the '28 targets.

    了不起。然後或許只需要後續跟進。我知道之前有個問題涉及到戰略格局之類的方面,我相信你能說的肯定有限。不過,能否稍微談談市場環境呢?你們一直在按計劃推進,而且在某些方面甚至提前完成了 2028 年的目標。

  • But when you look at like where the market sits today, you've got some pressure on academic and pharma, even though things might be getting better and unclear if customers want to deal with less players. So while you're executing when you think about Qiagen's ability to win or to be successful to create shareholder value as a stand-alone versus maybe maybe as part of a bigger company like has anything changed over the last year or two, just given the market dynamics?

    但從目前的市場狀況來看,學術界和製藥業都面臨一些壓力,儘管情況可能正在好轉,但客戶是否願意與更少的參與者打交道仍不明朗。所以,在執行過程中,當你思考 Qiagen 作為一家獨立公司與作為一家更大的公司的一部分相比,其贏得勝利或成功創造股東價值的能力時,考慮到市場動態,過去一兩年裡情況是否有所改變?

  • Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

    Thierry Bernard - Chief Executive Officer, Managing Director, Member of the Executive Board

  • We have all seen that that the market dynamic has been impacted by volatility and uncertainties over the last two years and three years, especially in research and academia, I think clinical has been a bit better. To your question, Qiagen has a clear plan for sales for our pipeline for new launches for profitability. We disclosed that plan in New York in June '24. And so far, we are executing as per this plan. This is where we focus.

    我們都看到,在過去兩三年裡,市場動態受到了波動和不確定性的影響,尤其是在研究和學術界,我認為臨床上的情況要好一些。關於您的問題,Qiagen 針對新產品上市的獲利能力製定了明確的銷售計劃。我們在 2024 年 6 月於紐約公佈了該計劃。目前為止,我們正按照這個計劃執行。這是我們關注的重點。

  • Yes, the market has become more difficult. But as I said, we found also solution to continue to support our growth in addition to our organic growth. Those are the acquisition of very interesting technologies frankly or pass. We will continue to do that. Qiagen invest and will continue to invest on average between 9% to 10% of our sales into research and development.

    是的,市場競爭變得更加激烈了。但正如我所說,除了自身的有機成長之外,我們也找到了繼續支持我們成長的解決方案。坦白說,這些都是非常有趣的技術的獲取,否則就作罷。我們將繼續這樣做。Qiagen 一直並將繼續把銷售額的 9% 到 10% 平均投入研發。

  • This translates into launches of new products, 3 new systems, for example, in Sample tech this year. This is unprecedented. So it's clear that should laboratory in research and academia start again to invest in capital expense. We are coming with new solutions. Qiagen will probably will be 1 of their priorities.

    這意味著今年將推出新產品,例如 Sample tech 今年將推出 3 個新系統。這是史無前例的。因此,很明顯,科學研究和學術界的實驗室應該重新開始進行資本支出投資。我們將提出新的解決方案。Qiagen很可能成為他們的優先考慮對象之一。

  • This is what I can say is that the market has not been easier, more volatile, but the fundamentals of the market, both life science and clinical remains extremely strong. When we will have more visibility on economic evolution and funding, I think it's fair to say single-digit a mid-single-digit growth profile for this market is perfectly acceptable and realistic.

    我可以肯定地說,市場並沒有變得更容易,反而更加波動,但生命科學和臨床市場的基本面依然非常強勁。當我們對經濟發展和資金狀況有更清晰的了解時,我認為可以公平地說,該市場個位數到中等個位數的成長前景是完全可以接受和現實的。

  • Operator

    Operator

  • Doug Schenkel, Wolf Research.

    道格‧申克爾,狼研究公司。

  • Douglas Schenkel - Analyst

    Douglas Schenkel - Analyst

  • Hey guys, thank you for taking my questions. One on guidance and then one on disclosure requirements. Simply put, I'm having a hard time getting the math to work. It could be me, but let's, for a second, assume it's not.

    大家好,感謝你們回答我的問題。一篇是關於指導原則的,一篇是關於資訊揭露要求的。簡而言之,我很難把數學運算弄清楚。可能是我,但我們先假設不是我。

  • If we grow revenue around 5% reported, if operating margin remained flat net of deals, if we keep nonoperating items about flat year-over-year, and we reduced share count to $209 million, I think those are all your key guidance assumptions as well as you provided tax rate. If I put this together, you end up actually above $2.60 per share, if I'm doing the basic math, right, you guided to $2/50 or better.

    如果報告收入增長約 5%,如果扣除交易後的營業利潤率保持不變,如果我們保持非經營性項目同比基本持平,並且我們將股份數量減少到 2.09 億股,我認為這些就是你們所有的關鍵指導假設,以及你們提供的稅率。如果我把這些加起來,最終每股價格實際上會超過 2.60 美元,如果我沒算錯的話,你的目標是每股 2.50 美元甚至更高。

  • What are we missing? So that's the first question. The second on disclosure requirements. Keeping in mind that you cited, I think it was German disclosure requirements as one 1 of the key reasons that you disclosed the plan when you did I'm wondering what would be the logical next required disclosure. Obviously, a new hire would need to be disclosed.

    我們遺漏了什麼?這是第一個問題。第二點是關於資訊揭露要求。考慮到你提到的情況,我認為德國的資訊揭露要求是你當時披露該計劃的關鍵原因之一,我想知道接下來合乎邏輯的揭露要求是什麼。顯然,新員工的聘用需要對外公佈。

  • But is there anything else under regulations that you would likely have to disclose in advance of that event.

    但根據相關規定,是否還有其他需要您在活動開始前揭露的資訊?

  • Roland Sackers - Managing Director, Chief Financial Officer, Member of the Executive Board

    Roland Sackers - Managing Director, Chief Financial Officer, Member of the Executive Board

  • I do not want to disappoint you, on your numbers, but I do think you look like that some of your team is missing one number because one number of cost is significantly going to change with its net interest contribution because we clearly did an acquisition, we clearly did a significant share buyback program is $500 million.

    我不想讓你們失望,關於你們的數字,但我認為你們團隊似乎漏掉了一個數字,因為成本中的一項數字會隨著淨利息貢獻而發生顯著變化,因為我們顯然進行了一項收購,我們顯然進行了一項重大的股票回購計劃,金額為 5 億美元。

  • So the net interest number is probably somewhere between $40 million and $45 million down. So that is all the number you are missing in your calculation. And yes, on disclosure requirement, again, is complicated. So luckily enough, I assume never becoming a lawyer and we're clearly working with our lawyers on this topic all the time.

    因此,淨利息支出可能在 4,000 萬美元到 4,500 萬美元之間。這就是你計算中缺少的所有數字。是的,關於資訊揭露要求,情況確實很複雜。所以幸運的是,我估計自己永遠不會成為律師,而我們顯然一直在就這個問題與律師合作。

  • Again, the general rule, if there's material news in the market regardless of which topic and you have the feeling that there is information in the market, which is clearly based on call it, lead information or change your share price into a significant extent.

    再次強調,一般規則是,如果市場上出現重大新聞,無論涉及哪個主題,並且你感覺市場上有信息,而這些信息顯然是基於預測、領先信息或大幅改變你的股價而得出的。

  • The company has to comment on that. And that is regardless of any topic, right? And so I would say that is a framework. As I said, we typically leave these decisions to to judge and again, any kind of information if that is important, an event which we have to preannounce or not, you haven't seen anything from Qiagen so far.

    該公司對此尚未回應。而且這與任何話題都無關,對吧?所以我認為這是一個框架。正如我所說,我們通常將這些決定留給法官來判斷,而且,任何重要的信息,例如我們需要提前宣布的事件,到目前為止,你們還沒有看到 Qiagen 的任何消息。

  • Operator

    Operator

  • That will conclude our question-and-answer session. At this time, I'd like to turn the call back over to Mr. Bernard for any additional or closing remarks.

    我們的問答環節到此結束。此時,我想把電話交還給伯納德先生,請他補充或作總結發言。

  • Daniel Wendorff - Vice President of Head of Relations

    Daniel Wendorff - Vice President of Head of Relations

  • Thank you very much. I would like to close this conference call and thank you for your participation. If you have any questions or comments, please do not hesitate to contact us. Thank you very much.

    非常感謝。我謹宣布本次電話會議結束,感謝各位的參與。如果您有任何疑問或意見,請隨時與我們聯繫。非常感謝。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes the conference call. Thank you for joining and have a pleasant day. Goodbye.

    女士們、先生們,本次電話會議到此結束。感謝您的參與,祝您有個愉快的一天。再見。